Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 521 - 530 of 785 studies

Respiratory

A Multinational, Long-Term, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])

Musculoskeletal

IDUN: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI) (IDUN)

Cancer and neoplasms

A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy versus Observation after First-line Induction Therapy in Participants with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma with Unmutated IGHV (SOUNDTRACK-C1)

Neurological

A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy (Sparkle)

Musculoskeletal

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping (SAFARI44)

Sink-related cleaning practices to prevent transmission of pathogens in healthcare settings

Neurological

CHTT227A12301: A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease (INVEST HD)

A qualitative study examining patients' experiences with a neurological condition that requires occupational therapy cognitive assessment, exploring different areas of focus across impairment-based and occupation-based screens and assessments

A Phase 1/2 Open-label, Dose-escalation, and Dose-expansion Study of mRNA-4194 in Participants with Lynch Syndrome (INTERCEPT-Lynch)

Prospective study of a novel culture-free system for direct pathogen ID and antimicrobial susceptibility testing (RaPIDS)